FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953296880> ?p ?o ?g. }

• W2953296880 endingPage "888" @default.
• W2953296880 startingPage "884" @default.
• W2953296880 abstract "Abstract Extensive data support the safety of direct oral anticoagulants compared with vitamin K antagonists in patients with non‐valvular atrial fibrillation, leading to a significantly increase in the use of these compounds in clinical practice. However, there is no compelling evidence supporting the use of direct oral anticoagulant in individuals who are intubated or have a percutaneous endoscopic gastrostomy (PEG): patients with several co‐morbidities are underrepresented in clinical trials, so the best long‐term strategy for anticoagulation is difficult to ascertain. The aim of the present report was to evaluate the safety and efficacy of edoxaban administered via PEG in a patient with heart failure and a history of atrial fibrillation affected by amyotrophic lateral sclerosis (ALS). A 71‐year‐old man with atrial fibrillation, advanced ALS, type II diabetes mellitus, and hypertension presented to the emergency department with dyspnoea and tachycardia. Because vitamin K antagonist and rivaroxaban 15 mg were dropped because of difficult international normalized ratio control (time in therapeutic range <30%) and severe haematuria, respectively, edoxaban 30 mg (crushed pill) daily was administered based on the patient's weight of 58 kg. Mean edoxaban plasma concentration–time profiles were measured, as anti‐Xa activity, 2 h before and at 2, 6, and 22 h after drug administration and then compared with the pharmacokinetic profile of edoxaban 30 mg in healthy subjects. An additional testing of steady‐state peak plasma concentration of edoxaban after 10 days and a 30 day follow‐up were evaluated. The values of the pharmacokinetic parameters, analysed with a non‐compartmental analysis by PKSolver module, showed that C max and AUC 0→ t were only slightly higher than those observed in healthy subjects, while the half‐life and observed clearance were significantly longer and lower, respectively, than in normal subjects. Steady‐state peak plasma concentration of edoxaban was very similar to the levels reported in healthy subjects, and neither relevant bleeding nor thromboembolic event was reported at a 30 day follow‐up. These results support safe and effective anticoagulation with edoxaban 30 mg but suggest caution with the use of full dose of edoxaban (60 mg daily) in this kind of patients. We report, for the first time, a safe and effective anticoagulation based on the administration of edoxaban 30 mg daily through PEG in a patient with advanced ALS, acute respiratory, and heart failure, presenting with Takotsubo syndrome and atrial fibrillation." @default.
• W2953296880 created "2019-06-27" @default.
• W2953296880 creator A5009430017 @default.
• W2953296880 creator A5022524234 @default.
• W2953296880 creator A5029130187 @default.
• W2953296880 creator A5031505042 @default.
• W2953296880 creator A5033442682 @default.
• W2953296880 creator A5056517566 @default.
• W2953296880 creator A5065403268 @default.
• W2953296880 creator A5078703572 @default.
• W2953296880 creator A5083235783 @default.
• W2953296880 creator A5091851552 @default.
• W2953296880 date "2019-06-11" @default.
• W2953296880 modified "2023-10-02" @default.
• W2953296880 title "Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy" @default.
• W2953296880 cites W2023562457 @default.
• W2953296880 cites W2078537626 @default.
• W2953296880 cites W2093049209 @default.
• W2953296880 cites W2109355833 @default.
• W2953296880 cites W2113047681 @default.
• W2953296880 cites W2126116248 @default.
• W2953296880 cites W2151514200 @default.
• W2953296880 cites W2170189969 @default.
• W2953296880 cites W2263934434 @default.
• W2953296880 cites W2587580509 @default.
• W2953296880 cites W2624642778 @default.
• W2953296880 cites W2791037961 @default.
• W2953296880 cites W2794091447 @default.
• W2953296880 cites W2872695204 @default.
• W2953296880 cites W2886022688 @default.
• W2953296880 doi "https://doi.org/10.1002/ehf2.12434" @default.
• W2953296880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6676270" @default.
• W2953296880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31184800" @default.
• W2953296880 hasPublicationYear "2019" @default.
• W2953296880 type Work @default.
• W2953296880 sameAs 2953296880 @default.
• W2953296880 citedByCount "4" @default.
• W2953296880 countsByYear W29532968802020 @default.
• W2953296880 countsByYear W29532968802022 @default.
• W2953296880 countsByYear W29532968802023 @default.
• W2953296880 crossrefType "journal-article" @default.
• W2953296880 hasAuthorship W2953296880A5009430017 @default.
• W2953296880 hasAuthorship W2953296880A5022524234 @default.
• W2953296880 hasAuthorship W2953296880A5029130187 @default.
• W2953296880 hasAuthorship W2953296880A5031505042 @default.
• W2953296880 hasAuthorship W2953296880A5033442682 @default.
• W2953296880 hasAuthorship W2953296880A5056517566 @default.
• W2953296880 hasAuthorship W2953296880A5065403268 @default.
• W2953296880 hasAuthorship W2953296880A5078703572 @default.
• W2953296880 hasAuthorship W2953296880A5083235783 @default.
• W2953296880 hasAuthorship W2953296880A5091851552 @default.
• W2953296880 hasBestOaLocation W29532968801 @default.
• W2953296880 hasConcept C10138342 @default.
• W2953296880 hasConcept C112705442 @default.
• W2953296880 hasConcept C126322002 @default.
• W2953296880 hasConcept C162324750 @default.
• W2953296880 hasConcept C2776301958 @default.
• W2953296880 hasConcept C2776704044 @default.
• W2953296880 hasConcept C2778661090 @default.
• W2953296880 hasConcept C2779161974 @default.
• W2953296880 hasConcept C2780075904 @default.
• W2953296880 hasConcept C2780290652 @default.
• W2953296880 hasConcept C42219234 @default.
• W2953296880 hasConcept C54400483 @default.
• W2953296880 hasConcept C71924100 @default.
• W2953296880 hasConceptScore W2953296880C10138342 @default.
• W2953296880 hasConceptScore W2953296880C112705442 @default.
• W2953296880 hasConceptScore W2953296880C126322002 @default.
• W2953296880 hasConceptScore W2953296880C162324750 @default.
• W2953296880 hasConceptScore W2953296880C2776301958 @default.
• W2953296880 hasConceptScore W2953296880C2776704044 @default.
• W2953296880 hasConceptScore W2953296880C2778661090 @default.
• W2953296880 hasConceptScore W2953296880C2779161974 @default.
• W2953296880 hasConceptScore W2953296880C2780075904 @default.
• W2953296880 hasConceptScore W2953296880C2780290652 @default.
• W2953296880 hasConceptScore W2953296880C42219234 @default.
• W2953296880 hasConceptScore W2953296880C54400483 @default.
• W2953296880 hasConceptScore W2953296880C71924100 @default.
• W2953296880 hasIssue "4" @default.
• W2953296880 hasLocation W29532968801 @default.
• W2953296880 hasLocation W29532968802 @default.
• W2953296880 hasLocation W29532968803 @default.
• W2953296880 hasOpenAccess W2953296880 @default.
• W2953296880 hasPrimaryLocation W29532968801 @default.
• W2953296880 hasRelatedWork W1972269502 @default.
• W2953296880 hasRelatedWork W1986307049 @default.
• W2953296880 hasRelatedWork W2195369357 @default.
• W2953296880 hasRelatedWork W2292941107 @default.
• W2953296880 hasRelatedWork W2572920622 @default.
• W2953296880 hasRelatedWork W2793392713 @default.
• W2953296880 hasRelatedWork W3173880122 @default.
• W2953296880 hasRelatedWork W4206007300 @default.
• W2953296880 hasRelatedWork W4319019627 @default.
• W2953296880 hasRelatedWork W2902339249 @default.
• W2953296880 hasVolume "6" @default.
• W2953296880 isParatext "false" @default.
• W2953296880 isRetracted "false" @default.
• W2953296880 magId "2953296880" @default.

• next